Shockwave Reducer Demonstrates Consistent, Positive Results

Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory AnginaSANTA CLARA, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced that investigators presented six-month data from the full population of the REDUCER-I study, alongside interim long-term follow-up results

Related Keywords

United Kingdom , Brompton , Medway , Harefield , Hillingdon , Belgium , Canada , United States , Utrecht , Netherlands , De Hoef , Noord Holland , London , City Of , Canadian , Stefan Verheye , Scott Shadiow , Michael Foley , Debbie Kaster , Rasha Al Lamee , European Union , Nasdaq , Lung Institute , Imperial College , National Heart , Shockwave Medical Inc , Canadian Cardiovascular Society , University Medical Center Utrecht , Exchange Commission , Six Month Results , Trial Add , Positive Evidence , Coronary Sinus Reducer , Treat Refractory , Shockwave Reducer , Annual Scientific Sessions , American College , Ranil De Silva , Royal Brompton , Harefield Hospitals , New England Journal , Principal Investigator , Shockwave Coronary Sinus , Shockwave Medical , Intravascular Lithotripsy , Breakthrough Device , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Refractory Angina , Ymptoms Of Angina , Observational Study , Cardiovascular Disease , Reducer , Treatment Options ,